Evaluation of the hepatotoxic potential of citalopram in rats

ILGIN S., DAĞAŞAN F., BURUKOĞLU DÖNMEZ D., BAYSAL M., ATLI EKLİOĞLU Ö.

ISTANBUL JOURNAL OF PHARMACY, cilt.50, sa.3, ss.188-194, 2020 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 50 Sayı: 3
  • Basım Tarihi: 2020
  • Doi Numarası: 10.26650/istanbuljpharm.2019.0081
  • Dergi Adı: ISTANBUL JOURNAL OF PHARMACY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.188-194
  • Anahtar Kelimeler: Citalopram, hepatotoxicity, hepatic biomarker, liver histology, oxidative status, INDUCED LIVER-INJURY, SEROTONIN REUPTAKE INHIBITORS, DRUG, ANTIDEPRESSANTS, ESCITALOPRAM, METABOLITES, MECHANISMS, DIAGNOSIS, PLACEBO
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Background and Aims: Citalopram is a selective serotonin reuptake inhibitor with a high potency which is occasionally prescribed and used to treat major depression associated with mood disorders as a first-line drug. According to the results of previous studies, evidence of hepatotoxicity related to citalopram treatment were limited and conflicting. Therefore, we aimed to evaluate the hepatotoxicity potential of sub-chronic citalopram administration.